The cost-effectiveness of cefazolin compared to anti-staphylococcal penicillins for the treatment of methicillin-sensitive Staphylococcus aureus bacteremia.
24 Oct, 2021 | 23:41h | UTCRelated:
Meta-Analysis: Cefazolin vs. Antistaphylococcal Penicillins for MSSA Bacteremia
Commentaries on Twitter
While Cefazolin and anti-staphylococcal penicillins (ASPs), such as nafcillin, are the preferred treatments for MSSA bacteremia it looks more and more like Cefazolin is really the preferred approach. https://t.co/6FVVEWMxBY
— Daniel Griffin MD PhD (@DanielGriffinMD) October 8, 2021
New in OFID: The use of cefazolin is a cost-effective strategy for the treatment of methicillin-sensitive S. aureus bacteremia and, when clinically appropriate, results in health care cost-savings.
?: https://t.co/lRfsZdMjLJ#IDSAJournals @PaulSaxMD @DrJLi @ElMylonakis pic.twitter.com/hhzik4ppUW
— IDSA (@IDSAInfo) October 8, 2021